**ARUP** LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Report |**FINAL**

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

## Patient: Patient, Example

| | |
|---|---|
| **DOB** | 2/24/1957 |
| **Gender:** | Female |
| **Patient Identifiers:** | 01234567890ABCD, 012345 |
| **Visit Number (FIN):** | 01234567890ABCD |
| **Collection Date:** | 00/00/0000 00:00 |

# MPL Mutation Detection by Capillary Electrophoresis

ARUP test code 2005545

MPL Results

Not Detected

A mutation was not detected in the MPL gene. MPL variants other than S505N, W515K, W515L, and W515A or below the limit of detection of the assay may not be identified.

This result has been reviewed and approved by ███████████ ███████████

INTERPRETIVE INFORMATION: MPL Mutation Detection by Capillary Electrophoresis
This test is designed to detect W515K, W515L, W515A, and S505N mutations in exon 10 of the MPL gene. Detection of MPL mutation is used for diagnosis of patients with myeloproliferative neoplasms and suggests a diagnosis of either primary myelofibrosis (PMF) or essential thrombocythemia (ET) in a subset of patients with non-mutated JAK2.

METHODOLOGY: DNA is isolated and amplified using allele-specific PCR for codons 505 and 515 of the MPL gene. The resulting amplicons are resolved via fragment analysis by capillary electrophoresis to detect the presence of W515K, W515L, W515A, and S505N mutations.

LIMITATIONS: Mutations other than those specified above, or at other locations within the MPL gene or in other genes will not be detected.

Limit of detection for this test is 5 percent mutant allele.

The results of this test must always be interpreted within the patient's clinical context and in conjunction with other relevant data. Results should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES** | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-137-402534
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 2 | Printed: 5/30/2023 2:51:23 PM
4848

800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

| VERIFIED/REPORTED DATES | | | | |
|---|---|---|---|---|
| Procedure | Accession | Collected | Received | Verified/Reported |
| MPL Results | 23-137-402534 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |

## END OF CHART

**H=High, L=Low, \*=Abnormal, C=Critical**

Patient: Patient, Example
ARUP Accession: 23-137-402534
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 |  Printed: 5/30/2023 2:51:23 PM
4848